Efficacy of autologous mesenchymal stem cell treatment in dogs with Elbow Dysplasia and OA
This presentation explores the outcomes of a longitudinal veterinary clinical study assessing the use of intra-articular autologous adipose-derived mesenchymal stem cells (MSCs) combined with leukocyte-poor platelet-rich plasma (PRP) in 415 dogs suffering from naturally occurring elbow osteoarthritis (OA) unresponsive to conventional treatments. Conducted within a veterinary regenerative medicine (RM) referral practice, the study utilised a standardised protocol targeting all identified musculoskeletal pathology. The results showed rapid and sustained improvements in pain reduction, functional mobility, and overall quality of life, with positive effects lasting up to five years. While highlighting the potential of MSCs as part of a multimodal OA treatment strategy, the study also underlines the importance of using scientifically validated MSC and PRP products. Various outcome measurement tools were employed to objectively evaluate therapeutic success, including pressure algometry, stance analysis, goniometry, and the VetMetrica™ HRQL tool.
- 1. Therapeutic Benefits of MSCs in Canine OA
- 2. Long-Term Efficacy and Safety of Stem cell therapy in treatment of Canine elbow OA
- 3. Standardised Treatment Protocols
- 4. Importance of Outcome Measurement Tools
- 5. Role of Regenerative Medicine in Multimodal OA Management
- 6. Product Validation and Clinical Relevance
){kind=logo}
){kind=logo}
){kind=logo}
)
)
)
)
)
)
)
)
){kind=logo}
)
)
){kind=logo}
)
)
)
)
)
)
)
)
){kind=logo}
){kind=logo}